Immunogenicity of pembrolizumab in patients with advanced tumors
Journal for ImmunoTherapy of Cancer, 2019 Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug
Marianne J. H. van Vugt +14 more
doaj +1 more source
Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]
, 2016 Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios +4 more
core +3 more sources
BMC CancerBackground Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC).
Andrea Necchi +15 more
doaj +1 more source
89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
Journal for ImmunoTherapy of Cancer, 2020 Background To better predict response to immune checkpoint therapy and toxicity in healthy tissues, insight in the in vivo behavior of immune checkpoint targeting monoclonal antibodies is essential.
Annelies Jorritsma-Smit +5 more
doaj +1 more source
PLoS ONE, 2021 BackgroundThe phase III KEYNOTE-604 study confirmed the benefit of pembrolizumab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Taken into account the clinical benefits of pembrolizumab and its
Qiao Liu +7 more
doaj +1 more source
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]
, 2019 Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence +2 more
core +2 more sources
Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting [PDF]
, 2019 The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of ...
Girard, N +4 more
core +1 more source
Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer. [PDF]
, 2019 Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers. These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including, but not limited to ...
Adashek, Jacob J +3 more
core
Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The Galectin-3 signature in NSCLCs [PDF]
, 2019 Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking.
Bartolazzi A. +4 more
core +1 more source
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. [PDF]
, 2018 Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression of programmed ...
Che, James +10 more
core +3 more sources